Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
Adaptive Biotechnologies (ADPT) will participate in investor conferences hosted by Jefferies in London and Piper Sandler in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adaptive Biotechnologies (ADPT) will participate in investor conferences hosted by Jefferies in London and Piper Sandler in New York.
The Jefferies Global Healthcare Conference presentation is scheduled for November 18, 2026, at 4:00 p.m. Greenwich Mean Time. The Piper Sandler 38th Annual Healthcare Conference fireside chat will take place on December 2, 2026, at 4:00 p.m. Eastern Time. Live and archived webcasts will be available through the Investors section of www.adaptivebiotech.com.
Details
Market Reaction – ADPT
On Nov 11, the first trading day after this news, the latest delayed price for ADPT is 6.35% above the previous close. Our momentum scanner has recorded 29 alerts for this stock so far that day. The latest delayed price is $31.23. Relative volume is above average at 1.7x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), ), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
- Jefferies Global Healthcare Conference in London, UK
Presentation on Wednesday, November 18, 2026, at 4:00 p.m. Greenwich Mean Time
- Piper Sandler 38th Annual Healthcare Conference in New York, NY
Fireside chat on Wednesday, December 2, 2026, at 4:00 p.m. Eastern Time
Interested parties may access live and archived webcasts of the session on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision, and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
